Literature DB >> 12054676

Inhibition of cGMP-dependent protein kinase II by its own splice isoform.

Stepan Gambaryan1, Alois Palmetshofer, Margarita Glazova, Albert Smolenski, Gunnar Ingi Kristjansson, Michael Zimmer, Suzanne M Lohmann.   

Abstract

cGMP- and cAMP-dependent protein kinases (cGK I, cGK II, and cAK) are important mediators of many signaling pathways that increase cyclic nucleotide concentrations and ultimately phosphorylation of substrates vital to cellular functions. Here we demonstrate a novel mRNA splice isoform of cGK II arising from alternative 5' splicing within exon 11. The novel splice variant encodes a protein (cGK II Delta(441-469)) lacking 29 amino acids of the cGK II Mg-ATP-binding/catalytic domain, including the conserved glycine-rich loop consensus motif Gly-x-Gly-x-x-Gly-x-Val which interacts with ATP in the protein kinase family of enzymes. cGK II Delta(441-469) has no intrinsic enzymatic activity itself, however, it antagonizes cGK II and cGK I, but not cAK. Thus, the activation and cellular functions of cGK II may be determined not only by intracellular cGMP levels but also by alternative splicing which may regulate the balance of expression of cGK II versus its own inhibitor, cGK II Delta(441-469).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12054676     DOI: 10.1016/S0006-291X(02)00412-6

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Multigene family encoding 3',5'-cyclic-GMP-dependent protein kinases in Paramecium tetraurelia cells.

Authors:  Roland Kissmehl; Tim P Krüger; Tilman Treptau; Marine Froissard; Helmut Plattner
Journal:  Eukaryot Cell       Date:  2006-01

2.  Cyclic GMP-dependent protein kinase II inhibits cell proliferation, Sox9 expression and Akt phosphorylation in human glioma cell lines.

Authors:  F J Swartling; M Ferletta; M Kastemar; W A Weiss; B Westermark
Journal:  Oncogene       Date:  2009-06-22       Impact factor: 9.867

3.  The constitutively active PKG II mutant effectively inhibits gastric cancer development via a blockade of EGF/EGFR-associated signalling cascades.

Authors:  Yan Wu; Miaomiao Yuan; Wenbin Su; Miaolin Zhu; Xiaoyuan Yao; Ying Wang; Hai Qian; Lu Jiang; Yan Tao; Min Wu; Ji Pang; Yongchang Chen
Journal:  Ther Adv Med Oncol       Date:  2018-02-01       Impact factor: 8.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.